# Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

> **NCT00003808** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** theophylline

## Key facts

- **NCT ID:** NCT00003808
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08-11
- **Primary completion:** 2002-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003808, "Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00003808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*